📰 GenCure and UT San Antonio have signed an agreement to collaborate on cell therapy research and testing. 🧪
🔬 GenCure will provide materials for UTSA researchers to generate induced pluripotent stem cells (iPSCs).
⚙️ In return, UTSA will provide testing services for GenCure’s process development and cGMP facilities.
🤝 The collaboration aims to accelerate the development of stem cell therapeutics for clinical use.
🔬 GenCure will provide materials for UTSA researchers to generate induced pluripotent stem cells (iPSCs).
⚙️ In return, UTSA will provide testing services for GenCure’s process development and cGMP facilities.
🤝 The collaboration aims to accelerate the development of stem cell therapeutics for clinical use.
📢 GenCure and UT San Antonio Join Forces to Revolutionize Stem Cell Therapy!
Introduction:
The University of Texas at San Antonio (UTSA) and GenCure, a subsidiary of BioBridge Global, have signed a master services agreement to collaborate on the development of cellular therapy products, services, and testing. This collaboration will provide UTSA with research starting materials and GenCure with capability development and testing services.
Main points:
- The expanded agreement between GenCure and the UTSA Stem Cell Core Lab allows UTSA researchers to access starting materials provided by GenCure for the isolation and reprogramming of adult stem cells to generate induced pluripotent stem cells (iPSCs).
- UTSA will provide testing services for materials manufactured by GenCure’s process development and cGMP facilities.
- The collaboration aims to facilitate training development, consulting services, and access to equipment and related research services unique to each site.
- The Stem Cell Core at UTSA enhances research by providing high-quality iPSCs and their progeny to researchers in Texas and nationwide.
- The collaboration between UTSA and GenCure will accelerate the development of stem cell therapeutics for clinical applications.
Conclusion:
The collaboration between UTSA and GenCure is focused on advancing cellular therapy research and development. By combining their expertise and resources, the partnership aims to accelerate the translation of stem cell therapeutics to the clinic, ultimately benefiting patients in need of innovative treatments.
